- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NeuroSense Announces First Quarter 2024 Business Update | 37 | PR Newswire | CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides... ► Artikel lesen | |
| 22.04. | NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease | 56 | PR Newswire | CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced... ► Artikel lesen | |
| 18.04. | NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting | 34 | PR Newswire | Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels
CAMBRIDGE,... ► Artikel lesen | |
| 12.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.04. | NeuroSense Therapeutics sheds 6%, on $4.5M direct private offering | 1 | Seeking Alpha | ||
| 10.04. | Lonza links with NeuroSense to detect exosome-based biomarkers | 75 | Pharmaceutical Technology | ||
| 09.04. | Lonza, NeuroSense Enter Alliance for ALS Candidate | 269 | Contract Pharma | ||
| 09.04. | NeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-market | 57 | RTTNews | ||
| 09.04. | Lonza arbeitet mit Biotechunternehmen Neurosense bei Nervenkrankheit zusammen | 47 | cash | ||
| 09.04. | NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics | 128 | PR Newswire | NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field
Lonza to develop, optimize, and qualify a method... ► Artikel lesen | |
| 08.04. | NeuroSense Therapeutics GAAP EPS of -$0.83 misses by $0.01 | 1 | Seeking Alpha | ||
| 05.04. | NeuroSense Announces Year End 2023 Financial Results and Provides Business Update | 52 | PR Newswire | CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported... ► Artikel lesen | |
| 05.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 04.04. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 20.03. | Neurosense Therapeutics Ltd expected to post a loss of 20 cents a share - Earnings Preview | 4 | Reuters | ||
| 22.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 21.02. | NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial | 170 | PR Newswire | PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
Standard ALS Measure ALSFRS-R already demonstrated a statistically significant... ► Artikel lesen | |
| 07.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.02. | NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule | 309 | PR Newswire | CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced... ► Artikel lesen | |
| 30.01. | NeuroSense Flat on New ALS Treatment | 3 | Baystreet.ca |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,575 | -3,37 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,045 | +4,50 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,808 | -2,80 % | Impulse setzen - Cardiol Therapeutics, Evotec, Redcare Pharmacy Aktie | Für risikobewusste Anleger ist die Pharma- und Biotechsparte ein lukrativer Markt für Investitionen. Die Branche wächst seit Jahrzehnten und auch für die kommenden Jahre wird mit einem Wachstum von... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,946 | +9,75 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 23,130 | +1,80 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ONCOLYTICS BIOTECH | 1,090 | +1,87 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| CIDARA THERAPEUTICS | 12,510 | -1,34 % | Cidara Therapeutics, Inc. - 8-K, Current Report | ||
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,025 | +1,49 % | Assertio Holdings Q1 2024 Earnings Preview | ||
| SIGA TECHNOLOGIES | 10,150 | +7,52 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | -0,20 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,390 | +13,18 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,410 | +4,23 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,750 | +3,07 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen |
Das Unternehmen NEUROSENSE THERAPEUTICS LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,070 (+5,56 %) liegt der Kurs bei 1,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
